GLP-1 Therapies Newsletter
Issue #48August 3, 20267 studies

Stop the drug, regain the weight: pooled data puts the average rebound at 7%

GLP-1 drugs keep working — until you stop taking them.

A week of new research mapped what happens to your body, your brain, your gut, and your bank account when these medications enter or exit the picture.

Quit the Drug, Get the Weight Back 📉

A new meta-analysis pooled 17 studies and 3,793 people who stopped approved weight-loss medications and tracked what happened next:

  • Average weight regain after stopping: 7.2% of body weight. Tirzepatide quitters rebounded hardest at 13%, liraglutide the least at 4.8%, and semaglutide landed in the middle at 7.2%.
  • In three head-to-head trials, people who stopped their medication gained roughly 14 percentage points more than people who kept taking it — a gap that held across drug classes, study designs, and countries.
  • The pattern tracks initial efficacy: the drugs that work best produce the steepest comebacks when stopped.

Why it matters: The data increasingly frames obesity pharmacotherapy less like a course of antibiotics and more like blood pressure medication — something the body may need indefinitely to hold the result.

🔗 Cureus Review 🗓️ Jul 31

Key Findings

Oral Semaglutide Tested for Alcohol Use Disorder 🍺

  • A phase 2 randomized trial published in the American Journal of Psychiatry evaluated oral semaglutide in adults with alcohol use disorder — one of the first controlled human tests of this idea.
  • The trial measured alcohol craving and consumption directly, moving beyond the observational signals that have dominated this conversation so far.
💡 Controlled trial evidence on GLP-1 drugs and alcohol is finally arriving.
🥇 Top 1% journal 🔗 The American journal of psychiatry Journal Article 🗓️ Jul 29

Real-World GLP-1 Rankings Don't Perfectly Mirror Trial Results 📊

  • A retrospective cohort study using the All of Us database compared five GLP-1 drugs head-to-head in a diverse US population with obesity, with and without type 2 diabetes.
  • The relative ordering of weight loss seen in clinical trials was largely — but not perfectly — preserved in routine care, suggesting real-world complexity that trial conditions don't fully capture.
💡 Trial rankings mostly hold in the real world, but the gaps shift.
Top 20% journal 🔗 Drug design, development and therapy Comparative Study 🗓️ Jul 28

Compounded Semaglutide Carries Impurity Risks 💉

  • Researchers tested multiple samples of follow-on and compounded semaglutide and liraglutide products and found impurity profiles that raise potential immunogenicity concerns.
  • A separate study found that untrained adults using grey-market peptide semaglutide without a prescription completed only about 44% of required preparation steps correctly, with errors that could cause incorrect dosing, needle sticks, or infections.
💡 Compounded and grey-market GLP-1 products introduce risks the originals don't.
Top 20% journal 🔗 Pharmaceutical research Journal Article 🗓️ Jul 30

A New Oral GLP-1 Pill Clears Its First Human Test 💊

  • Zenagamtide, a once-daily oral drug that activates GLP-1, amylin, and calcitonin receptors simultaneously, completed a phase 2 dose-finding trial in adults with type 2 diabetes, published in The Lancet.
  • Separately, TERN-601, another once-daily oral small-molecule GLP-1 drug, reported safety and early efficacy data from phase 1 and 2 studies in adults with obesity or overweight.
💡 The race to replace the weekly injection with a daily pill is accelerating.
🥇 Top 1% journal 🔗 Lancet (London, England) Journal Article 🗓️ Jul 30

GLP-1 Drugs Linked to Fewer Antidepressant Prescriptions 🧠

  • A prescription sequence analysis of Australian pharmacy data found that starting a GLP-1 drug was associated with lower rates of subsequently starting an antidepressant and lower rates of starting medication for substance use disorder.
  • No significant associations appeared for antipsychotics, antidementia drugs, or other neuropsychiatric categories — suggesting the signal is specific, not a blanket brain effect.
💡 GLP-1 use tracks with fewer depression and addiction prescriptions, not all psych drugs.
🥉 Top 5% journal 🔗 Clinical pharmacology and therapeutics Journal Article 🗓️ Jul 31

Tirzepatide Improves Liver Disease in Real-World Patients 🫀

  • A real-world multicenter study evaluated tirzepatide in patients with obesity and metabolic dysfunction-associated steatotic liver disease and found meaningful improvements in hepatic steatosis alongside weight loss.
  • A separate meta-analysis of six randomized controlled trials found that dual and triple GLP-1-based drugs increased the likelihood of liver disease resolution by more than threefold compared to placebo, with liver fat content falling by an average of nearly 45 percentage points.
💡 Liver disease may be the next major indication these drugs quietly own.
🎖️ Top 10% journal 🔗 Frontiers in endocrinology Multicenter Study 🗓️ Jul 28

Implications

The week's evidence collectively tightens one uncomfortable loop: GLP-1 drugs work, but stopping them reverses the benefit; staying on them raises cost and access barriers that disproportionately hit lower-income patients. The unresolved tension is whether any behavioral, dietary, or microbiome-based intervention can meaningfully slow the rebound when patients do stop.

Studies in this issue

Primary sources used for this newsletter.

  1. Weight Regain After Stopping Weight Loss Medications: A Review and Combined Analysis
    main storyCureus2026-07-31PMID 42534203
  2. Effectiveness and safety of once-daily oral zenagamtide, a new combined GLP-1 and amylin receptor drug, in adults with type 2 diabetes: a multi-center, randomized, placebo-controlled dose study
    key findingLancet (London, England)2026-07-30PMID 42532079
  3. Tirzepatide and fatty liver disease linked to metabolism in people with obesity: a real-world multicenter study
    key findingFrontiers in endocrinology2026-07-28PMID 42518535
  4. Impurities and Possible Immune Reactions Linked to Generic and Mixed Versions of Glucagon-like Peptide-1 Receptor Agonists
    key findingPharmaceutical research2026-07-30PMID 42533250
  5. Real-world weight loss with different GLP-1 medicines in the All of Us study
    key findingDrug design, development and therapy2026-07-28PMID 42518911
  6. Testing Oral Semaglutide as a Treatment for Alcohol Use Disorder
    key findingThe American journal of psychiatry2026-07-29PMID 42522065
  7. Patterns of Prescriptions for Glucagon-Like Peptide-1 Drugs and Their Links to Mental Health Conditions
    key findingClinical pharmacology and therapeutics2026-07-31PMID 42533561

Continue reading

All GLP-1 Therapies issues